Literature DB >> 7964811

Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud).

M Emre1, G C Leslie, C Muir, N J Part, R Pokorny, R C Roberts.   

Abstract

In a double blind, placebo controlled, cross over study the correlations between single doses (2, 4, and 8 mg), plasma concentrations, and antispastic action of tizanidine were investigated in 16 patients with extensor spasticity of the legs due to multiple sclerosis. An electrogoniometer was used to assess muscle tone at knee extensors, applying Wartenberg's pendulum test. Blood samples, a clinical assessment of muscle tone by the Ashworth scale, and muscle strength by the British Medical Research Council scale were obtained concomitantly. Confirmatory analysis using the change in the relaxation index (R2 value) 1.5 hours after each treatment, showed a statistically significant (p = 0.0123) linear dose-response relation between single doses and antispastic action of tizanidine. Further statistical analysis showed a strong within patient linear correlation between plasma concentrations and antispastic action at 4 and 8 mg doses (p = 0.014 and 0.004 respectively), but only weak between patient correlations. The analysis of the dose-plasma concentration relation showed results consistent with linear pharmacokinetics. The comparison of changes in the R2 ratio with concomitant Ashworth scores showed a significant correlation between the two. It is concluded that there are linear correlations between single doses, plasma concentrations, and antispastic action of tizanidine. Because of the strong within patient but weak between patient correlation between plasma concentrations and antispastic action of tizanidine the effective doses should be determined individually.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964811      PMCID: PMC1073186          DOI: 10.1136/jnnp.57.11.1355

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.

Authors:  B ASHWORTH
Journal:  Practitioner       Date:  1964-04

2.  Pendulousness of the legs as a diagnostic test.

Authors:  R WARTENBERG
Journal:  Neurology       Date:  1951 Jan-Feb       Impact factor: 9.910

3.  Descriptive data analysis: a concept between confirmatory and exploratory data analysis.

Authors:  K Abt
Journal:  Methods Inf Med       Date:  1987-04       Impact factor: 2.176

4.  Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis.

Authors:  E Knutsson; A Mårtensson; L Gransberg
Journal:  J Neurol Sci       Date:  1982-02       Impact factor: 3.181

5.  Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury.

Authors:  C J Mathias; J Luckitt; P Desai; H Baker; W el Masri; H L Frankel
Journal:  J Rehabil Res Dev       Date:  1989

6.  Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.

Authors:  M C Hoogstraten; R J van der Ploeg; W vd Burg; A Vreeling; S van Marle; J M Minderhoud
Journal:  Acta Neurol Scand       Date:  1988-03       Impact factor: 3.209

7.  The pharmacology of 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole (DS 103-282), a novel myotonolytic agent.

Authors:  A C Sayers; H R Bürki; E Eichenberger
Journal:  Arzneimittelforschung       Date:  1980

8.  Treatment of spasticity with tizanidine in multiple sclerosis.

Authors:  Y Lapierre; S Bouchard; C Tansey; D Gendron; W J Barkas; G S Francis
Journal:  Can J Neurol Sci       Date:  1987-08       Impact factor: 2.104

9.  Does the Wartenberg pendulum test differentiate quantitatively between spasticity and rigidity? A study in elderly stroke and Parkinsonian patients.

Authors:  R A Brown; D A Lawson; G C Leslie; A MacArthur; W J MacLennan; M E McMurdo; W J Mutch; N J Part
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-09       Impact factor: 10.154

10.  Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.

Authors:  N Hassan; D L McLellan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-12       Impact factor: 10.154

View more
  8 in total

Review 1.  Outcomes assessment of drug treatment in multiple sclerosis clinical trials.

Authors:  M Malone; B Lomaestro
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

Review 2.  Spasticity after stroke. Epidemiology and optimal treatment.

Authors:  C F O'Brien; L C Seeberger; D B Smith
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

3.  Selective depression of medium-latency leg and foot muscle responses to stretch by an alpha 2-agonist in humans.

Authors:  S Corna; M Grasso; A Nardone; M Schieppati
Journal:  J Physiol       Date:  1995-05-01       Impact factor: 5.182

Review 4.  Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

5.  Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

Authors:  Herbert R Henney; Michael Chez
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

6.  Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm.

Authors:  Daniela Cristina Vitale; Cateno Piazza; Tiziana Sinagra; Vincenzo Urso; Francesco Cardì; Filippo Drago; Salvatore Salomone
Journal:  Clin Drug Investig       Date:  2013-12       Impact factor: 2.859

7.  Management of Tizanidine Withdrawal Syndrome: A Case Report.

Authors:  A Suárez-Lledó; A Padullés; T Lozano; S Cobo-Sacristán; M Colls; R Jódar
Journal:  Clin Med Insights Case Rep       Date:  2018-02-13

8.  The relation between Ashworth scores and neuromechanical measurements of spasticity following stroke.

Authors:  Laila Alibiglou; William Z Rymer; Richard L Harvey; Mehdi M Mirbagheri
Journal:  J Neuroeng Rehabil       Date:  2008-07-15       Impact factor: 4.262

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.